Digoxin Use and Digoxin Toxicity in the Post-DIG Trial Era

Journal of Cardiac Failure

Volumn 12, Issue 5, 2006, Pages 343-346

  Hussain, Zainal ^a   Swindle, Jason ^a   Hauptman, Paul J ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Digoxin; Drug toxicity; Heart failure; Practice patterns

Indexed keywords

DIGOXIN; DIGOXIN ANTIBODY;

ADULT; AGED; ARTICLE; BREATHING DISORDER; CONTROLLED STUDY; DISABILITY; DISORDERS OF ACID BASE BALANCE; DISORIENTATION; DRUG EXPOSURE; DRUG FATALITY; DRUG SAFETY; DRUG USE; FEMALE; HEART ARREST; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGISTER; UNSPECIFIED SIDE EFFECT;

AGED; CARDIOTONIC AGENTS; COMMERCE; DIGOXIN; DRUG UTILIZATION; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; REGISTRIES;

EID: 33744515806     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2006.02.005     Document Type: Article

References (28)

1. Flather M.D., Yusuf S., Køber L., Pfeffer M., Hall A., Murray G., et al. Long-term ACE inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. Lancet 355 (2000) 1575-1581
2. Garg R., and Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 273 (1995) 1450-1456
3. Krum H., Roecker E.B., Mohacsi P., et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS study. JAMA 289 (2003) 712-718
4. MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure. Lancet 353 (1999) 2001-2007
5. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999) 709-717
6. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336 (1997) 525-533
7. Rathore S.S., Wang Y., and Krumholz H.M. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 347 (2002) 1403-1411
8. Packer M. End of the oldest controversy in medicine. Are we ready to conclude the debate on digitalis?. N Engl J Med 336 (1997) 575-576
9. Stafford R.S., Furberg C.D., Finkelstein S.N., Cockburn I.M., Alehegn T., and Ma J. Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002. JAMA 291 (2004) 54-62
10. Nananda C.F., McLaughlin T.J., Soumerai S.B., Hosmer D.W., Yarzebski J., Gurwitz J., et al. The impact of clinical trials on the use of medications for acute myocardial infarction: results of a community based study. Arch Intern Med 156 (1996) 54-60
11. Tu K., Mamdani M.M., Jacka R.M., Forde N.J., Rothwell D.M., and Tu J.V. The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. CMAJ 168 (2003) 553-557
12. Rich M.W., Brooks K., and Luther P. Temporal trends in pharmacotherapy for congestive heart failure at an academic medical center 1990-1995. Am Heart J 135 (1998) 367-372
13. Smith N.L., Chan J.D., Rea T.D., Wiggins K.L., Gottdiener J.S., Lumley T., et al. Time trends in the use of beta blockers and other pharmacotherapies in older adults with congestive heart failure. Am Heart J 148 (2004) 710-717
14. Fonarow G.C., Adams Jr. K.F., Abraham W.T., Yancy C.W., Boscardin W.J., et al. ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 293 (2005) 572-580
15. Watson W.A., Litovitz T.L., Klein-Schwartz W., Rodgers G.C., Youniss J., Reid N., et al. 2003 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 22 (2004) 335-404
16. Young J.B. Whither Withering's legacy: digoxin's role in our contemporary pharmacopeia for heart failure. J Am Coll Cardiol 46 (2005) 505-507
17. McDermott M.M., Feinglass J., Lee P., Mehta S., Schmitt B., Lefevre F., et al. Heart failure between 1986 and 1994: temporal trends in drug prescribing practices, hospital readmissions and survival at an academic medical center. Am Heart J 134 (1997) 901-909
18. Camerini A., Griffo R., Fabbri G., Aspromonte N., Ingrilli F., Lucci D., et al. Use of digitalis in the treatment of heart failure: data from the Italian Network on Congestive Heart Failure (IN-CHF). Ital Heart J 5 (2004) 523-529
19. Saunders K.B., Amerasinghe A.K.C.P., and Saunders K.L. Dose of digoxin prescribed in the UK compared with France and the USA. Lancet 349 (1997) 833-836
20. Gambassi G., Forman D.E., Lapane K.L., Mor V., Sgadari A., Lipsitz L.A., and Bernabei R. Management of heart failure among very old persons living in long-term care: has the voice of trials spread?. Am Heart J 139 (2000) 85-93
21. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. American College of Cardiology web site. Available at: http://www.acc.org/clinical/guidelines/failure//index.pdf.
22. Adams K.F., Lindenfeld J., Arnold J.M.O., Baker D.W., Barnard D.H., Baughman K.L., et al. Executive summary: HFSA 2006 Comprehensive heart failure practice guideline. J Cardiac Failure 12 (2006) 10-38
23. Adams Jr. K.F., Patterson J.H., Gattis W.A., OConnor C.M., Lee C.R., Schwartz T.A., et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digoxin investigation group trial: a retrospective analysis. J Am Coll Cardiol 46 (2005) 497-504
24. Rathore S.S., Curtis J.P., Wang Y., Bristow M.R., and Krumholz H.M. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289 (2003) 871-878
25. Hauptman P.J., and Kelly R. Cardiovascular drugs: digitalis. Circulation 99 (1999) 1265-1270
26. Williamson K.M., Thrasher K.A., Fulton K.B., Allen LaPointe N.M., Dunham G.D., Cooper A.A., et al. Digoxin toxicity: an evaluation in current clinical practice. Arch Intern Med 158 (1998) 2444-2449
27. Gandhi A.J., Vlasses P.H., Morton D.J., and Bauman J.L. Economic impact of digoxin toxicity. Pharmacoeconomics 12 (1997) 175-181
28. Olshansky B., Rosenfeld L.E., Warner A.L., Solomon A.J., O'Neill G., Sharma A., et al. AFFIRM Investigators. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 43 (2004) 1201-1208